Dr Reddy aims to create his own space in the vaccine segment: GV Prasad

According to its co-chairman and chief executive, GV Prasad, pharmaceutical major Dr Reddy’s Laboratories plans to create its own space in the vaccine segment.

“Currently, our biologics / biosimilars business is focused on the development and commercialization of mAb biosimilars. In the short to medium term in this business, we will seek to add value to our core business, leverage existing marketing and other capabilities, ”said Prasad. Activity area.

New partnerships

Dr Reddy’s, based in Hyderabad, who is now the trademark custodian of the Russian vaccine Sputnik V in India following an agreement with the Russian Direct Investment Fund (RDIF), will also explore licensing and partnership opportunities for them. biosimilars with the right partners in emerging markets, he added. .

In the long term, the company’s goal in the biosimilars business is to establish a presence in regulated markets. The in-house development of biologics / biosimilars has a long gestation period.

“Besides the development of biosimilars, using existing biologics capabilities and our experience / learnings from Sputnik V, we will consider the viral vaccine space and viral vector platforms as a new growth platform. . The Wockhardt wallet that we acquired last year also contained vaccines. We see this as a long-term growth engine, ”said Prasad.

On the R&D front, the drugmaker said, “We will continue to strengthen our product pipeline, with an additional set of biosimilar introductions in its development pipeline as we move forward into the Phase 3 clinical trial. Rituximab. “

In the first quarter ended in June of this fiscal year, R&D expenses were 453 crore, representing a turnover of 9.2%, with an increase of 14% year-on-year, in line with the increase in the development pipeline in its biosimilars and generics activities, including the development of molecules linked to Covid.

Increase production

Regarding the amount of Sputnik V’s bid in India, Prasad said the supply will increase over the next two to three months as six contract manufacturers, including Hetero and Gland Pharma, with whom RIDF has already signed pacts , are starting or increasing production.

“We are very careful. We only provide the first dose of the vaccine if the second dose is also available to avoid any problems for those taking the first dose of their vaccine, ”he said.

Sputnik V is administered in India in two doses with an interval of 21 days. Both doses of the vaccine should be taken in the same hospital, as the second dose is available after the first dose to avoid a later shortage.

Source link

About Margie Peters

Check Also

Rupifi Raises $ 25 Million in Serie A Funding Round

Fintech start-up Rupifi has raised a funding round of $ 25 million from Bessemer Venture …

Leave a Reply

Your email address will not be published. Required fields are marked *